Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
暂无分享，去创建一个
Chiun Hsu | A. Hansen | Se-Hoon Lee | R. Cohen | A. Algazi | S. Ejadi | S. Saraf | Pradeep Thanigaimani | Jonathan D. Cheng | J. Mehnert | E. V. van Brummelen | C. Even | C. le Tourneau | E. van Brummelen